Total Funding
29
33
Total FundingPost-IPO Debt raised
Growth Score
-27 pts
Heat Score
-14 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
174634
BerGenBio is clinical-stage biopharma developing first-in-class selective AXL kinase inhibitors to treat multiple aggressive cancers.
David Micklem: Co-Founder, CTO ,Director of Biomarkers & Assay Development- Rune Skeie: CFO
About the Company
BerGenBio is a clinical stage oncology biotech company, which is engaged in developing therapeutics against novel drug targets that drive aggressive cancers. Its drug candidate bemcentinib (BGB324) is in clinical development as a novel treatment for a variety of cancers.
